An Early Look: See Why Aprea Therapeutics (Nasdaq: APRE) is Topping Our Watchlist Today

*Sponsored Krypton Street Announces Aprea Therapeutics (Nasdaq: APRE) As Our Next Potential Breakout Idea! And Here’s Why… Analyst Coverage: HC Wainwright & Co.’s $20 Target On (APRE) Suggests Over 750% Upside Potential. Limited Float: (APRE) Has Less Than 5M Shares In Its Float—Setting the Stage For Significant Swing Potential if Demand Begins to Shift.  Under The Radar: With A Market Cap Under $15M, (APRE) Could be On the Cusp of Major Growth Potential. Strong Fiscal Position: (APRE) Holds $22.8M In Ca-sh And Equivalents, Plus An Additional $18M Potential From Warrant Exercises. Disruptive Cancer Research: (APRE) Is Pioneering ATRN-119 And APR-1051, Therapies Targeting DDR-Related Mutations To Redefine Cancer Treatment. First-In-Class Molecule: ATRN-119 Is The First Macrocyclic ATR Inhibitor In Clinical Trials, Offering Selectivity And Potency Over Older Treatments. Promising Clinical Data: ATRN-119 Shows Strong Tumor Control, While APR-1051 Demonstrates Anti-Tumor Activity With Minimal Side Effects. Consider Taking a Look at Aprea Therapeutics (Nasdaq: APRE) While  It’s Still Early… March 11, 2025 Dear Reader, Here’s an early look why Aprea Therapeutics (Nasdaq: APRE) is topping our watchlist today. Few industries can match biotechnology's explosive potential, where a single discovery can quickly turn an overlooked company into a high-profile name. When a firm introduces groundbreaking scientific advancements, the market has the potential to react quickly—these innovations simply can't stay under the radar for long. Some breakthroughs, however, do more than capture attention—they have the potential to completely reshape the field. Aprea Therapeutics, Inc. (Nasdaq: APRE) is one little-known company that’s pushing forward in precision oncology with innovative research into synthetic lethality—an approach that could dramatically alter cancer treatment methods. And it’s not just us noticing—Benzinga reports that HC Wainwright & Co., one of the nation's oldest institutions, reiterated a $20 target for (APRE), signaling an upside potential of more than 750% from yesterday’s $2.32 range. Why Aprea Therapeutics (Nasdaq: APRE) Is Flying Under the Radar While large-cap companies may dominate the headlines, it’s often the small and micro-caps that offer the greatest growth potential.  With leaner operations, smaller revenue bases, and the ability to pivot quickly, these companies can scale rapidly when the right catalyst hits. Take Aprea Therapeutics (Nasdaq: APRE)—with a market cap under $15M and fewer than 5M shares in the float, this is a company operating with the kind of tight structure that has historically fueled explosive growth potential. Keep reading to see why Aprea Therapeutics (Nasdaq: APRE) is topping our watchlist this morning… (Tuesday 3/11/2025) Aprea Therapeutics (Nasdaq: APRE): Aiming to Redefine Precision Oncology Let’s cut straight to the chase: Aprea Therapeutics (Nasdaq: APRE) isn’t simply following the usual biotech script.  Rather, they're pursuing groundbreaking approaches with therapies that specifically target some of cancer’s most stubborn forms. These treatments aren’t incremental improvements—they could fundamentally alter how cancer care is delivered, potentially improving outcomes where current methods fall short. If you're interested in discovering a biotech firm with genuine vision and the capability to disrupt the traditional cancer treatment landscape, Aprea Therapeutics might just deserve your attention. Aprea Therapeutics (Nasdaq: APRE) Is Setting Its Sights on Major Oncology Breakthroughs While many biotech companies are merely trying to keep pace, Aprea Therapeutics is forging ahead with therapies designed to tackle challenging cancers through a concept called synthetic lethality. Instead of broad-spectrum, traditional treatments, they're developing highly selective therapies that target cancer cells' genetic vulnerabilities, potentially leading to fewer side effects and more effective outcomes. With several clinical milestones approaching, including significant data readouts, Aprea is demonstrating proactive leadership that positions it as a compelling name to watch closely. What Exactly Is Aprea Doing? Aprea Therapeutics (Nasdaq: APRE) is in the business of precision oncology, and not in the "here’s a generic treatment" way.  They’re pioneers in a groundbreaking concept called synthetic lethality. This isn’t just some buzzword thrown around by your typical biotech firm; this is a targeted approach that could actually make cancer treatments more effective and less toxic.  Their mission?  To stop tumors in their tracks by exploiting the very weaknesses in cancer cells that make them so dangerous. In addition to their groundbreaking therapies, Aprea Therapeutics (Nasdaq: APRE) has strengthened its position with a strategic evolution in its intellectual property (IP) portfolio.  This patent portfolio reflects their commitment to securing long-term value for their cutting-edge treatments.  The ATR inhibitor program is now protected by a strong estate, including four granted U.S. patents, 19 granted non-U.S. patents, and 16 pending applications, extending exclusivity through 2044.  This IP foundation is key for protecting the value of their assets as they advance treatments like ATRN-119 and APR-1051, which are currently in clinical trials targeting DDR-related mutations. They’re going after two major targets in the DNA Damage Response (DDR) system: ATR and WEE1.  These are not your everyday targets—these are the type of molecules that could make or break the future of cancer treatments. Aprea Therapeutics (Nasdaq: APRE)’s Precision Oncology: Two Inhibitors That Could Tackle Cancer with Unmatched Efficacy Aprea Therapeutics (Nasdaq: APRE) is making significant strides in the fight against cancer, with two potentially best-in-class inhibitors that could disrupt current cancer care. ATRN-119 Aprea Therapeutics (Nasdaq: APRE)’s ATRN-119 is a macrocyclic ATR inhibitor, and it stands out in a major way.  Unlike first-generation ATR inhibitors, which have been associated with serious toxicity and inconsistent dosing schedules, ATRN-119 has been engineered to be selective and highly potent.  This means patients could experience less toxicity, more effective continuous dosing, and a smoother treatment process overall.  In preclinical studies, ATRN-119 has shown strong tumor control, including in some of the most challenging genetic backgrounds.  This makes it a potential game-changer in the oncology space. APR-1051 If you’ve been following oncology, you’ve likely heard of WEE1 inhibitors.  But APR-1051 is different.  This inhibitor is structurally differentiated and demonstrates high selectivity.  Unlike other treatments that often disrupt multiple systems—leading to toxic side effects—APR-1051 is more targeted, focusing specifically on its cancer-related proteins while leaving healthy cells largely unaffected.  Early studies suggest that APR-1051 could suppress tumors without the typical hematologic toxicity (blood-related side effects) that often accompanies cancer treatments.  It shows strong potential for anti-tumor activity, especially in cancers with CCNE1 amplification—for example, ovarian cancer. Aprea Therapeutics (Nasdaq: APRE): Accelerating Progress in  Precision Oncology Aprea Therapeutics (Nasdaq: APRE) isn’t sitting on the sidelines—they’re rapidly advancing with their unique approach to cancer treatment. Recently, the company took a big step forward by implementing a strategic shift in its ABOYA-119 clinical trial, introducing a twice-daily (BID) dosing regimen for their first-in-class ATR inhibitor, ATRN-119. Why does this matter? Scientific evidence suggests more frequent dosing could keep therapeutic levels steady throughout the entire 24-hour cycle, potentially enhancing effectiveness.  In fact, the first patient has already started on a 550 mg twice-daily dose, kicking off a critical new phase of this groundbreaking trial. What's especially interesting here is that ATRN-119 is currently the only ATR inhibitor being tested with continuous twice-daily dosing.  That distinction alone could set Aprea apart, putting them ahead of the curve. By zeroing in on cancers with DNA damage response (DDR) mutations—where patients currently have few options—Aprea is positioned to potentially redefine what's achievable in cancer treatment. Why This Matters Right Now This kind of progress is exactly why Aprea Therapeutics (Nasdaq: APRE) is grabbing attention.  With promising early signs of clinical benefit already emerging for ATRN-119, and open-label data for their other key therapy APR-1051 expected later this year, Aprea Therapeutics (Nasdaq: APRE) is actively tackling significant unmet needs in cancer care. They’re targeting challenging cancers like ovarian, colorectal, prostate, and breast, areas that desperately need new treatments. Behind this momentum is a management team that's far from ordinary—they're experts and innovators in synthetic lethality and targeted cancer therapies.  Combine this leadership with strong intellectual property—protected by multiple U.S. patents—and robust financial backing (over $22M in cash, with additional capital available from warrant exercises), and you've got a compelling story. Bottom line: Aprea Therapeutics (Nasdaq: APRE) is a little-known biotech with big ambitions.  They have the fiscal stability, cutting-edge science, and strategic vision needed to potentially reshape cancer care. As we head deeper into 2025, Aprea Therapeutics (Nasdaq: APRE) is a company to keep on your radar. 7 Reasons Why Aprea Therapeutics (Nasdaq: APRE) is Topping Our Watchlist This Morning… 1. Analyst Coverage: HC Wainwright & Co.’s $20 target for Aprea Therapeutics (Nasdaq: APRE) suggests an upside potential of over 750% from today’s $2.32 range. 2. Limited Float: With a market cap under $15M & equivalents and fewer than 5M shares in the float, Aprea Therapeutics (Nasdaq: APRE) is a little-known company that could see significant growth potential if its treatments move forward as planned. 3. Strong Fiscal Position: Aprea Therapeutics (Nasdaq: APRE) holds $22.8M in ca-sh & equivalents, plus the potential for an additional $18M from warrant exercises, providing the fiscal strength to advance its innovative pipeline. 4. Disruptive Cancer Research: Aprea Therapeutics (Nasdaq: APRE) is pioneering ATRN-119 and APR-1051, two promising therapies targeting DDR-related mutations, which could redefine cancer treatment and tackle some of the most challenging cancers. 5. Innovative Dosing Strategy: The recent move to a twice-daily dosing regimen for ATRN-119 could optimize its efficacy, making it a strong contender in clinical trials and ahead of other therapies in development. 6. First-in-Class Molecule: ATRN-119 is the first macrocyclic ATR inhibitor in clinical trials, offering selectivity and potency—a key advantage over older, more toxic treatments. 7. Promising Clinical Data: Preclinical studies show ATRN-119 demonstrating strong tumor control, while APR-1051 is showing anti-tumor activity with minimal side effects, especially in difficult-to-treat cancers like ovarian cancer. Consider Adding Aprea Therapeutics (Nasdaq: APRE) To Your  Radar This Week… Aprea Therapeutics (Nasdaq: APRE) is a little-known company with strong upside potential, as indicated by HC Wainwright & Co.’s $20 target—which suggests 750% upside potential.  With a market cap under $15M and fewer than 5M shares in the float, (APRE) has significant growth potential, especially given its $22.8M in ca-sh. The company is leading the way with ATRN-119 and APR-1051, two innovative therapies targeting DDR-related mutations that could revolutionize cancer treatment.  The shift to a twice-daily dosing regimen for ATRN-119 enhances its efficacy, while its first-in-class status and promising preclinical data give (APRE) a competitive edge in oncology. We have all eyes on (APRE) right now. Take a look at (APRE) while it’s still early. Also—keep an eye out for my next update—it could be out before the bell rings. Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KryptonStreet is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of Media 1717 LLC owns and operates kryptonstreet . com (“KS”). From time to time, KS will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: kryptonstreet.com/disclaimer/ *Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 03/10/2025 and ending on 03/11/2025 to publicly disseminate information about (APRE:US) via digital communications. Under this agreement, Media 1717 LLC has been paid seven thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Media 1717 LLC, TD Media LLC, or their members own shares of (APRE:US). Please see important disclosure information here: https://kryptonstreet.com/disclosure/apre/#details

Media 1717 LLC | 6586 W Atlantic Ave Unit #2086 | Delray Beach, FL 33446 US Unsubscribe | Update Profile | Constant Contact Data Notice